Elisa Agostinetto
YOU?
Author Swipe
View article: RSC4All as a machine learning nomogram to predict RSClin™ results in HR+/HER2- node-negative early breast cancer
RSC4All as a machine learning nomogram to predict RSClin™ results in HR+/HER2- node-negative early breast cancer Open
View article: Managing relapses during or after adjuvant CDK4/6 inhibitors in HR-positive/HER2-negative early breast cancer: an emerging challenge
Managing relapses during or after adjuvant CDK4/6 inhibitors in HR-positive/HER2-negative early breast cancer: an emerging challenge Open
View article: Brain imaging screening in metastatic breast cancer: patients’ and physicians’ perspectives
Brain imaging screening in metastatic breast cancer: patients’ and physicians’ perspectives Open
These results underline the willingness of patients to know more about the prospects of BM development, in contrast to the lack of routine discussion of this topic by physicians. Further investigation is warranted to demonstrate the clinic…
View article: Neoadjuvant immune-modulating SBRT and anti-CD73 to increase response to anti-PD-L1 and chemotherapy in early ER+/HER2- breast cancer: primary endpoint and translational results from the randomized Neo-CheckRay trial
Neoadjuvant immune-modulating SBRT and anti-CD73 to increase response to anti-PD-L1 and chemotherapy in early ER+/HER2- breast cancer: primary endpoint and translational results from the randomized Neo-CheckRay trial Open
Patients with oestrogen receptor-positive (ER+), HER2-negative, early breast cancer (BC) have low pathological complete response (pCR) rates following neoadjuvant chemotherapy (NACT). Phase 3 trials showed that adding an anti-PD-1 immune c…
View article: Safety of having a subsequent pregnancy after prior diagnosis of breast cancer during pregnancy in young BRCA carriers
Safety of having a subsequent pregnancy after prior diagnosis of breast cancer during pregnancy in young BRCA carriers Open
View article: Breastfeeding after breast cancer in young <i>BRCA</i> carriers
Breastfeeding after breast cancer in young <i>BRCA</i> carriers Open
Background We investigated safety of breastfeeding after breast cancer in patients carrying germline BRCA pathogenic or likely pathogenic variants. Methods This was an international, multicenter, hospital-based, retrospective cohort study …
View article: Cardiovascular toxicity of breast cancer treatments: from understanding to enhancing survivorship care
Cardiovascular toxicity of breast cancer treatments: from understanding to enhancing survivorship care Open
View article: 416O Safety of having a subsequent pregnancy after a prior diagnosis of breast cancer during pregnancy (PrBC) in young BRCA carriers
416O Safety of having a subsequent pregnancy after a prior diagnosis of breast cancer during pregnancy (PrBC) in young BRCA carriers Open
View article: 192MO Primary endpoint of ROSALINE: A phase II neoadjuvant study of endocrine therapy (ET) and entrectinib in invasive lobular breast carcinoma (ILBC)
192MO Primary endpoint of ROSALINE: A phase II neoadjuvant study of endocrine therapy (ET) and entrectinib in invasive lobular breast carcinoma (ILBC) Open
View article: 154P Characteristics and outcomes of young BRCA carriers with triple-negative breast cancer (TNBC) according to histology subtype
154P Characteristics and outcomes of young BRCA carriers with triple-negative breast cancer (TNBC) according to histology subtype Open
View article: 268P Association between baseline body mass index and survival outcomes in BRCA carriers with breast cancer diagnosed at a young age: Results from an International cohort study
268P Association between baseline body mass index and survival outcomes in BRCA carriers with breast cancer diagnosed at a young age: Results from an International cohort study Open
View article: 277P Body mass index (BMI) and breast cancer (BC) risk according to subtypes: A systematic review and meta-analysis
277P Body mass index (BMI) and breast cancer (BC) risk according to subtypes: A systematic review and meta-analysis Open
View article: Association of statin use on survival outcomes of patients with early-stage HER2-positive breast cancer in the APHINITY trial
Association of statin use on survival outcomes of patients with early-stage HER2-positive breast cancer in the APHINITY trial Open
Purpose There is evidence that statins might improve the outcome of patients with breast cancer. The role of statins in patients with early HER2-positive breast cancer is unknown. Therefore, we explored the association between statin use a…
View article: Extended adjuvant endocrine therapy in early breast cancer: finding the individual balance
Extended adjuvant endocrine therapy in early breast cancer: finding the individual balance Open
Endocrine therapy (ET) is a cornerstone in the management of patients with hormone receptor-positive early breast cancer, which accounts for over 70% of cases worldwide. The efficacy of adjuvant ET for 5 years in reducing the risk of recur…
View article: Clinical characteristics and prognostic factors in patients with breast cancer and leptomeningeal metastases from a large registry of BMBC
Clinical characteristics and prognostic factors in patients with breast cancer and leptomeningeal metastases from a large registry of BMBC Open
View article: Clinical Behavior of Breast Cancer in Young <i>BRCA</i> Carriers and Prediagnostic Awareness of Germline <i>BRCA</i> Status
Clinical Behavior of Breast Cancer in Young <i>BRCA</i> Carriers and Prediagnostic Awareness of Germline <i>BRCA</i> Status Open
PURPOSE To investigate the clinical behavior of breast cancer in young BRCA carriers according to the specific BRCA gene ( BRCA1 v BRCA2 ) and the association of the timing of genetic testing (before v at diagnosis) with prognosis. METHODS…
View article: Prognostic implications of risk definitions from the monarchE and NATALEE trials
Prognostic implications of risk definitions from the monarchE and NATALEE trials Open
Background The monarchE and NATALEE trials employed different high-risk inclusion criteria. The main objective is to assess prognostic differences based on their inclusion criteria. Methods Patients with hormone receptor-positive/HER2-nega…
View article: Assisted Reproductive Technology in Young Brca Carriers with a Pregnancy after Breast Cancer: An International Cohort Study
Assisted Reproductive Technology in Young Brca Carriers with a Pregnancy after Breast Cancer: An International Cohort Study Open
View article: Drug-drug interactions between palbociclib and proton pump inhibitors in early breast cancer: an exploratory analysis of PALLAS (ABCSG-42/AFT-05/BIG-14-13/PrE0109)
Drug-drug interactions between palbociclib and proton pump inhibitors in early breast cancer: an exploratory analysis of PALLAS (ABCSG-42/AFT-05/BIG-14-13/PrE0109) Open
View article: Clinical Characteristics and Prognostic Factors in Patients with Breast Cancer and Leptomeningeal Metastases from a Large Registry of Bmbc
Clinical Characteristics and Prognostic Factors in Patients with Breast Cancer and Leptomeningeal Metastases from a Large Registry of Bmbc Open
View article: Characteristics and clinical outcomes of breast cancer in young BRCA carriers according to tumor histology
Characteristics and clinical outcomes of breast cancer in young BRCA carriers according to tumor histology Open
View article: Impact of hormone receptor status and tumor subtypes of breast cancer in young BRCA carriers
Impact of hormone receptor status and tumor subtypes of breast cancer in young BRCA carriers Open
In young BRCA carriers, differences in recurrence pattern and second primary breast cancer among hormone receptor-positive versus negative disease warrant consideration in counseling patients on treatment, follow-up, and risk-reducing surg…
View article: Characterization of HER2‐low breast cancer in young women with germline <i>BRCA1/2</i> pathogenetic variants: Results of a large international retrospective cohort study
Characterization of HER2‐low breast cancer in young women with germline <i>BRCA1/2</i> pathogenetic variants: Results of a large international retrospective cohort study Open
Background Breast cancer (BC) in women aged ≤40 years carrying germline pathogenetic variants (PVs) in BRCA1/2 genes is infrequent but often associated with aggressive features. Human epidermal growth factor receptor 2 (HER2)‐low‐expressin…
View article: Emerging treatments in HER2-positive advanced breast cancer: Keep raising the bar
Emerging treatments in HER2-positive advanced breast cancer: Keep raising the bar Open
View article: 160P Characteristics and outcomes of young breast cancer patients harboring BRCA pathogenic variants according to histologic subtype
160P Characteristics and outcomes of young breast cancer patients harboring BRCA pathogenic variants according to histologic subtype Open
Breast cancer (BC) in young women is often associated with germline BRCA pathogenic variants (PVs). Limited data exist on the impact of different histologic BC subtypes in young patients with a germline BRCA PV. In this multicenter retrosp…
View article: 266O Safety of assisted reproductive techniques in young BRCA carriers with a pregnancy after breast cancer: Results from an international cohort study
266O Safety of assisted reproductive techniques in young BRCA carriers with a pregnancy after breast cancer: Results from an international cohort study Open
Very limited evidence is available on the safety of assisted reproductive techniques (ART) in breast cancer (BC) patients harboring BRCA1/2 pathogenic variants (PVs). Hence, concerns remain among physicians counseling young BRCA carriers w…
View article: The long and winding road to biomarkers for immunotherapy: a retrospective analysis of samples from patients with triple-negative breast cancer treated with pembrolizumab
The long and winding road to biomarkers for immunotherapy: a retrospective analysis of samples from patients with triple-negative breast cancer treated with pembrolizumab Open
View article: Circulating tumor DNA for predicting recurrence in patients with operable breast cancer: a systematic review and meta-analysis
Circulating tumor DNA for predicting recurrence in patients with operable breast cancer: a systematic review and meta-analysis Open
View article: The Impact of Initial Tumor Response on Survival Outcomes of Patients With HER2-Positive Advanced Breast Cancer Treated With Docetaxel, Trastuzumab, and Pertuzumab: An Exploratory Analysis of the CLEOPATRA Trial
The Impact of Initial Tumor Response on Survival Outcomes of Patients With HER2-Positive Advanced Breast Cancer Treated With Docetaxel, Trastuzumab, and Pertuzumab: An Exploratory Analysis of the CLEOPATRA Trial Open
View article: Impact of Hormone Receptor Status and Tumor Subtypes on Clinical Behavior and Outcomes of Breast Cancer in Young&nbsp;BRCA&nbsp;Carriers
Impact of Hormone Receptor Status and Tumor Subtypes on Clinical Behavior and Outcomes of Breast Cancer in Young BRCA Carriers Open